X

Earnings Summary Of Jubilant Pharmova Limited For Q3 FY23

Jubilant Pharmova Limited (NSE: JUBLPHARMA) was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in November 2020. The company was founded in 1978 and is headquartered in Noida, India. It has a presence in over 100 countries worldwide and operates through several subsidiaries such as Jubilant Generics, Jubilant HollisterStier, Jubilant Radiopharma, and Jubilant Pharma.

For the quarter ended December 31, 2022, Jubilant Pharmova reported a consolidated Revenue of ₹1533.22 crore, which represents an increase of 18% YoY. The company’s Radipharma segment for the quarter stood at ₹613.21 crore, up 20% YoY, meanwhile the Net loss after tax was ₹16.04 crore. The Sterile Injectibles segment reported a revenue of ₹295.32 crore, which remained same YoY. The Contract Manufacturing of Sterile Injectables segment reported a revenue of ₹300.57 crore, up 13.6% YoY.

Categories: Earnings
Related Post